New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...

The court directed the firm to pay Ms Gichuki 10 months’ salary as compensation would be adequate in the circumstances ...

Patients who were prescribed drugs for restless legs syndrome (RLS) have said doctors did not warn them about significant ...

GSK has joined a lengthening list of companies that have paused diversity, equity, and inclusion (DEI) targets under pressure ...

Medical breakthroughs and regulatory approvals ... beating its benchmark by 218 percentage points (see more details here).

The respiratory segment, often influenced by seasonal factors, registered a 1.1% increase in value but faced a 4.6% decline ...

With Sunday’s Academy Awards ceremony in the rearview mirror, GSK is looking ahead to a potential blockbuster premiere of its ...

Secondary endpoint analyses from the trials showed 'significant improvements' in patients treated with the antibody.

Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...

GSK to showcase latest research at the International RSV Symposium to advance RSV prevention in adults: London, UK Saturday, March 8, 2025, 14:00 Hrs [IST] GSK plc will share its ...

London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review the Biologics License ...

In the SWIFT and ANCHOR trials, depemokimab demonstrated statistically significant reductions in nasal polyp size, ...